Scholarlink

Background <p>This study was designed to determine the seroprevalence of HTLV among multi-transfused patients in the South of Iran.</p> Methods <p>All patients with <i>β-thalassemia</i> major and those on regular hemodialysis from the cities of Dashtestan, Bushehr, Genaveh, Tangestan, and Kangan participated in this study. Serum samples were tested for HTLV-I/II antibodies by ELISA, and Western Blot confirmed seropositive samples. Moreover, hepatitis-related markers were assessed using serological assays.</p> Results <p>Of 134 thalassemia patients, 6 cases (4.48%, 95% CI: 1.83%-9.91%) were positive for HTLV-I/II antibodies, all of which were confirmed by Western blot as HTLV-1. The hemodialysis patients and the controls were negative for HTLV-I/II antibodies. Of 6 HTLV-1 seropositive thalassemia patients, 4 cases were positive for anti-HCV antibodies (66.7%), and 2 cases were positive for anti-HEV IgG (33.4%). HTLV-1 seropositive thalassemia patients were negative for HBV infection criteria, while 5 of 6 patients (83.33%) had HBsAb in their samples. HTLV-1 seropositivity increased with age and was higher among single patients, female patients, residents of Kangan, patients receiving blood transfusions every two weeks, and Fars patients. Nevertheless, the seroprevalence of HTLV-1 was not statistically associated with marital status, gender distribution, place of residency, frequency of blood transfusion, age, ethnicity, or level of education.</p> Conclusion <p>This study reports a relatively high seroprevalence of HTLV-1 among patients with <i>β-thalassemia</i> major, highlighting a high risk of HTLV-1 exposure in the thalassemia population. Therefore, an evaluation of introducing HTLV donor screening is recommended to reduce the transmission of HTLV-1 infection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Seroprevalence of human T-cell lymphotropic virus and transfusion-transmitted viral hepatitis markers among hemodialysis and thalassemia patients in the South of Iran

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月13日

查看全文
  • Fatemeh Farshadpour,
  • Zahra Avazzadeh,
  • Fatemeh Dehghanian,
  • Samad Akbarzadeh,
  • Ali Movahed,
  • Katayoun Vahdat,
  • Manoochehr Makvandi,
  • Narges Obeidi,
  • Reza Taherkhani

摘要

Background

This study was designed to determine the seroprevalence of HTLV among multi-transfused patients in the South of Iran.

Methods

All patients with β-thalassemia major and those on regular hemodialysis from the cities of Dashtestan, Bushehr, Genaveh, Tangestan, and Kangan participated in this study. Serum samples were tested for HTLV-I/II antibodies by ELISA, and Western Blot confirmed seropositive samples. Moreover, hepatitis-related markers were assessed using serological assays.

Results

Of 134 thalassemia patients, 6 cases (4.48%, 95% CI: 1.83%-9.91%) were positive for HTLV-I/II antibodies, all of which were confirmed by Western blot as HTLV-1. The hemodialysis patients and the controls were negative for HTLV-I/II antibodies. Of 6 HTLV-1 seropositive thalassemia patients, 4 cases were positive for anti-HCV antibodies (66.7%), and 2 cases were positive for anti-HEV IgG (33.4%). HTLV-1 seropositive thalassemia patients were negative for HBV infection criteria, while 5 of 6 patients (83.33%) had HBsAb in their samples. HTLV-1 seropositivity increased with age and was higher among single patients, female patients, residents of Kangan, patients receiving blood transfusions every two weeks, and Fars patients. Nevertheless, the seroprevalence of HTLV-1 was not statistically associated with marital status, gender distribution, place of residency, frequency of blood transfusion, age, ethnicity, or level of education.

Conclusion

This study reports a relatively high seroprevalence of HTLV-1 among patients with β-thalassemia major, highlighting a high risk of HTLV-1 exposure in the thalassemia population. Therefore, an evaluation of introducing HTLV donor screening is recommended to reduce the transmission of HTLV-1 infection.